By identifying signalling pathways essential to myopia development, Wu et al. found that anti-hypoxic drug salidroside and formononetin application can downregulate HIF-1α expression and eIF2α/mTOR phosphorylation, thereby halting myopia progression in humans. The gene discussed is EIF2A; the disease is myopia.